Exemestane, sold under the brand name Aromasin, is an oral medication categorized as an aromatase inhibitor. It is primarily used in the treatment of hormone-receptor positive breast cancer in postmenopausal women. The compound works by reducing the amount of estrogen produced in the body, thereby slowing or stopping the growth of cancer cells that rely on estrogen for their proliferation. It is often prescribed after other treatments, such as tamoxifen, have been used.
While its primary medical use is in oncology, exemestane is sometimes used off-label in other contexts, particularly in bodybuilding, to manage estrogen levels. Its half-life is approximately 24 hours. The typical timing for administration is flexible, and it can be taken with or without food. Exemestane is not an injectable medication and is not a controlled substance.
Deep dive
Tap a section to expand.
Known interactions
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Category rule: vitamin × medication
Note
Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).
Specific pairs are checked against a licensed source; confirm with your provider.
Frequently asked
Sources referenced
["U.S. Food and Drug Administration (FDA) - Aromasin (exemestane) Prescribing Information", "National Institutes of Health (NIH) - Office of Dietary Supplements (ODS)", "MedlinePlus - Exemestane", "PubChem - Exemestane", "DrugBank - Exemestane", "European Medicines Agency (EMA) - SmPC (Summary of Product Characteristics) for Aromasin", "National Cancer Institute (NCI)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the medication category or studied for the same goals.